Trial · NCT03126110
Adverse events5,742
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
41 to 60 of 5,742
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain | Gastrointestinal disorders | Phase 1 Group B: INCAGN01876 1.0 mg/kg Q2W, Then Nivolumab 240 mg Q2W | 1 | 5 | 1 |
| other | Abdominal pain | Gastrointestinal disorders | Phase 1 Group B: INCAGN01876 3.0 mg/kg Q2W, Then Nivolumab 240 mg Q2W | 0 | 4 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | Phase 1 Group B: INCAGN01876 5.0 mg/kg Q2W, Then Nivolumab 240 mg Q2W | 0 | 4 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | Phase 1 Group C: INCAGN01876 1.0 mg/kg Q2W + Ipilimumab 1 mg/kg Q6W | 0 | 4 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | Phase 1 Group C: INCAGN01876 3.0 mg/kg Q2W + Ipilimumab 1 mg/kg Q6W | 1 | 8 | 1 |
| other | Abdominal pain | Gastrointestinal disorders | Phase 1 Group C: INCAGN01876 5.0 mg/kg Q2W + Ipilimumab 1 mg/kg Q6W | 0 | 3 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | Phase 1 Group D: INCAGN01876 + Nivolumab + Ipilimumab | 0 | 6 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | Phase 2 Group C2 PD-1/PD-L1 RM: INCAGN01876 300 mg + Ipilimumab 1 mg/kg | 1 | 8 | 1 |
| other | Abdominal pain | Gastrointestinal disorders | Phase 2 Group F GC: INCAGN01876 300 mg + Nivolumab 240 mg | 3 | 16 | 3 |
| other | Abdominal pain | Gastrointestinal disorders | Phase 2 Group F SCCHN INCAGN01876 300 mg + Nivolumab 240 mg | 1 | 46 | 1 |
| other | Abdominal pain | Gastrointestinal disorders | Phase 2 Group F CC: INCAGN01876 300 mg + Nivolumab 240 mg | 6 | 18 | 6 |
| other | Abdominal pain | Gastrointestinal disorders | Phase 2 Group F PD-1/PD-L1 RM: INCAGN01876 300 mg + Nivolumab 240 mg | 0 | 4 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | Phase 2 Group F Biopsy: INCAGN01876 300 mg + Nivolumab 240 mg | 0 | 2 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | Total | 13 | 145 | 13 |
| other | Abdominal pain lower | Gastrointestinal disorders | Phase 1 Group A: INCAGN01876 1.0 mg/kg Q2W + Nivolumab 240 mg Q2W | 0 | 4 | 0 |
| other | Abdominal pain lower | Gastrointestinal disorders | Phase 1 Group A: INCAGN01876 3.0 mg/kg Q2W + Nivolumab 240 mg Q2W | 0 | 4 | 0 |
| other | Abdominal pain lower | Gastrointestinal disorders | Phase 1 Group A: INCAGN01876 5.0 mg/kg Q2W + Nivolumab 240 mg Q2W | 0 | 5 | 0 |
| other | Abdominal pain lower | Gastrointestinal disorders | Phase 1 Group A: INCAGN01876 10.0 mg/kg Q2W + Nivolumab 240 mg Q2W | 0 | 4 | 0 |
| other | Abdominal pain lower | Gastrointestinal disorders | Phase 1 Group B: INCAGN01876 1.0 mg/kg Q2W, Then Nivolumab 240 mg Q2W | 0 | 5 | 0 |
| other | Abdominal pain lower | Gastrointestinal disorders | Phase 1 Group B: INCAGN01876 3.0 mg/kg Q2W, Then Nivolumab 240 mg Q2W | 0 | 4 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03126110/events?page=3